Sign in with your email address username.


[Editorial] An Ebola vaccine: first results and promising opportunities

Today, The Lancet publishes the first results from a phase 3 cluster randomised trial of a novel Ebola virus vaccine. The study, sponsored and led by WHO, is a remarkable scientific and logistical achievement. In the midst of an extreme public health emergency, researchers, health workers, and community facilitators in Guinea included 7651 people in a trial to test the efficacy of a recombinant, replication-competent vesicular stomatitis virus-based vaccine expressing a surface glycoprotein of Ebola (Zaire).